BAVA:CPH
Bavarian Nordic A/S
236,80 DKK
arrow_downward
-1,82%(-4,40) 1K
13-okt, 17:00:00 (GMT+2) · DKK
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBAVA tikeri uchun statistika yaratilmoqda...
Ochish
240,00 DKK
Yuqori
242,20 DKK
Past
236,80 DKK
Bozor kapitali
19,12 mlrd
Oʻrtacha hajm
179,17 ming
Hajmi
198,62 ming
52 haftalik eng yuqori
243,70 DKK
52 haftalik eng past
171,30 DKK
Muomaladagi aksiyalar
79,27 mln
Xodimlar soni
2 ming
Ochish
240,00 DKK
Yuqori
242,20 DKK
Past
236,80 DKK
Bozor kapitali
19,12 mlrd
Oʻrtacha hajm
179,17 ming
Hajmi
198,62 ming
52 haftalik eng yuqori
243,70 DKK
52 haftalik eng past
171,30 DKK
Muomaladagi aksiyalar
79,27 mln
Xodimlar soni
2 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
GlobeNewswire
·
1 kun oldin
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Bavarian Nordic A/S haqida
CEOPaul Chaplin
Xodimlar soni1,91 ming
Asos solingan1-iyl, 1992
Bosh ofislar-
Sektor-
Veb-saytbavarian-nordic.com